Skip to content
2000
Volume 9, Issue 3
  • ISSN: 1570-1808
  • E-ISSN: 1875-628X

Abstract

The synthesis and structure-activity relationships (SAR) antitumor activities of monopyrazolic and bipyrazolic tripodal derivatives are reported here for the first time. The ten products were tested against three human cancer cell lines including breast (MDA-MB231), prostate (PC3) and colorectal (LoVo) cancers. In bipyrazolic series, most of them exhibited a moderate antitumor activity against three human cancer cell lines with an order of 5 > 7 > 8 in case of colorectal cancer and 5 > 7 ≈ 8 in case of breast and prostate cancers.

Loading

Article metrics loading...

/content/journals/lddd/10.2174/157018012799129792
2012-03-01
2025-11-02
Loading full text...

Full text loading...

/content/journals/lddd/10.2174/157018012799129792
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test